Aclarion Inc (ACON)vsVeeva Systems Inc Class A (VEEV)
ACON
Aclarion Inc
$1.74
-1.14%
HEALTHCARE · Cap: $5.62M
VEEV
Veeva Systems Inc Class A
$310.63
+2.45%
HEALTHCARE · Cap: $51.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 4127986% more annual revenue ($3.46B vs $83,770). VEEV leads profitability with a 29.3% profit margin vs 0.0%. VEEV earns a higher WallStSmart Score of 66/100 (B-).
ACON
Avoid33
out of 100
Grade: F
VEEV
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+41.0%
Fair Value
$299.84
Current Price
$310.63
$10.79 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 30.5% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Strong operational efficiency at 29.6%
17.6% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 30.5% demonstrates continued momentum.
Bull Case : VEEV
The strongest argument for VEEV centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.3% and operating margin at 29.6%. Revenue growth of 17.6% demonstrates continued momentum.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio. A P/E of 52.1x leaves little room for execution misses.
Key Dynamics to Monitor
ACON profiles as a hypergrowth stock while VEEV is a growth play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.21 — expect wider price swings.
ACON is growing revenue faster at 30.5% — sustainability is the question.
VEEV generates stronger free cash flow (231M), providing more financial flexibility.
Bottom Line
VEEV scores higher overall (66/100 vs 33/100), backed by strong 29.3% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is an innovative healthcare technology company focused on transforming the diagnosis and management of musculoskeletal conditions through advanced non-invasive imaging and data analytics. Leveraging machine learning capabilities, Aclarion provides healthcare professionals with actionable insights that improve clinical outcomes while optimizing cost-effective treatment pathways. As a key player in the digital health arena, the company is positioned to address the growing demand for effective diagnostic solutions, thereby enhancing patient care and management in a rapidly evolving healthcare environment. Aclarion's commitment to improving patient outcomes places it at the forefront of future healthcare delivery advancements.
Visit Website →Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?